In the BioHarmony Drug Report Database
Bulevirtide
Hepcludex (bulevirtide) is a protein pharmaceutical. Bulevirtide was first approved as Hepcludex on 2020-07-31. It has been approved in Europe to treat chronic hepatitis d.
Trade Name
|
Hepcludex |
|---|---|
Common Name
|
bulevirtide |
ChEMBL ID
|
CHEMBL4297711 |
Indication
|
chronic hepatitis d |
Drug Class
|
Peptides: antiviral peptides; antivirals |
Image (chem structure or protein)
